Multisystem Inflammatory Syndrome in Children
10
2
2
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
10.0%
1 terminated out of 10 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
AT1001 for the Treatment of COVID-19 Related MIS-C
MISC COVID-19 Study in Pediatric Population
Seroprevalence of SARS-Cov-2 Antibodies in Children
Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan
Incidence of MIS-C and Other Complications Following SARS-CoV-2 Infection
Genetic Risk Factors for Multi-system Inflammatory Syndrome in Children and Pediatric Post COVID Condition
Investigation of Prognostic Biomarkers, Host Factors and Viral Factors for COVID-19 in Children
Multisystem Inflammatory Syndrome In Children at Sohag University Hospital
COVID-19: Immunological Mechanisms in Multisystem Inflammatory Syndrome in Children
Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome